Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy
Will R. Geisen,
Justin Berger,
Chelsea Schwartz,
Abhimanyu Reddy,
Balaj Rai,
George Wadih,
Joshua Peck
Affiliations
Will R. Geisen
The Christ Hospital, Department of Pathology, Cincinnati, OH, United States; Corresponding author at: The Christ Hospital, Department of Internal Medicine, 2139 Auburn Avenue, Cincinnati, OH, 45219, United States.
Justin Berger
The Christ Hospital, Department of Pathology, Cincinnati, OH, United States
Chelsea Schwartz
The Christ Hospital, Department of Pathology, Cincinnati, OH, United States
Abhimanyu Reddy
The Christ Hospital, Department of Pathology, Cincinnati, OH, United States
Balaj Rai
The Christ Hospital, Department of Pathology, Cincinnati, OH, United States
George Wadih
The Christ Hospital, Department of Pathology, Cincinnati, OH, United States
Joshua Peck
Ohio Gastroenterology and Liver Institute, Cincinnati, OH, United States
The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We describe a gentleman who was treated with experimental therapies and subsequently developed cytomegalovirus colitis and hypovolemic shock. Additionally, this case validates colonoscopy as a mode to rule out concurrent infectious etiologies causing diarrhea in COVID-19-positive patients.
